That is 0 articles you have read today.
The Aporia is free and carries no advertising, so readers are the only
thing paying for it. If you are getting this much out of it, a small
donation is what keeps it independent.
Daily limit reached
You have read 0 articles today.
That is more than the 15 a day The Aporia gives away,
and well past what it can carry on nothing. Your allowance resets at
midnight.
There is no advertising here and nothing about you is sold, so readers
are the only thing paying for it. If the site is worth this much of
your day, it is worth a few dollars.
Everything else stays open: the
maps, the
directory and
search do
not count against this, and neither does re-opening something you have
already read today.
At an Aging Research & Drug Discovery conference, pharmaceutical companies presented findings from trials showing that GLP-1 drugs can reverse biological aging by two to three years for overweight or diabetic patients. Novo and Eli Lilly conducted studies involving thousands of participants using various methods like proteomic and epigenetic clocks to measure age prediction through blood samples. Geneticist Steve Horvath noted that a reduction of up to two years is significant, suggesting these drugs may act as geroprotectors. However, it remains unclear if the anti-aging effects would be consistent in healthy individuals without obesity or diabetes.
Written locally by qwen2.5:14b on 2026-10-11,
using this article's own text rather than the other coverage of the
same event (that is the story summary below).
Story summary
During the Aging Research & Drug Discovery conference, pharmaceutical companies presented findings from trials on GLP-1 drugs like Ozempic and Wegovy, which are reversing biological aging in overweight or diabetic patients by around two to three years. Geneticist Steve Horvath, who invented "aging clocks," described the effect as a strong indicator that these drugs could be classified as geroprotectors—medications that slow or reverse aging biologically. For instance, Novo Nordisk conducted a study involving 10,052 people, where half were given semaglutide and the other half a placebo, measuring changes through proteomic clocks to assess age-related risks. Eli Lilly also performed a similar but smaller-scale study using epigenetic clocks on their drug tirzepatide. These results suggest that GLP-1 drugs may offer significant benefits in aging research despite potential side effects.
Written for “GLP-1 Drugs Reverse Aging” on 2026-10-11,
grounded in this article and the 0 other(s) covering the same event.
During the Aging Research & Drug Discovery conference, the pharmaceutical companies shared their findings from several trials on the effects the medications have on aging.
asserted
medications → share → aging
And overweight or diabetic patients taking the medications saw a decreased age of around two or three years, a notable outcome according to one biological aging expert.
uncertain
patients → take → expert
“Two years is a pretty strong effect, in my book,” geneticist Steve Horvath, the inventor of aging clocks, said, adding that the data suggests GLP-1 drugs “are actually what is known as geroprotectors, medications that slow or possibly even reverse biologic aging.”
uncertain
that → age → aging
As part of their research, Novo took blood draws from 10,052 people, half on the drug semaglutide and half on a placebo.
asserted
Novo → take → placebo
The blood — collected at the start of the study as well as months later — was then measured with “proteomic clocks,” which use levels of key proteins to predict a person’s age and risk of dying.
asserted
which → collect → age
Eli Lilly performed a similar, yet smaller, study on their drug, tirzepatide, using “epigenetic” clocks that measure age by marking changes to a person’s DNA.
asserted
that → perform → DNA
In the search for scientific remedies for aging, Novo’s drug semaglutide (sold under the names Ozempic and Wegovy) may be the closest solution.
uncertain
drug → sell → names
The difference in aging varied widely, depending on which type of clock was used and what organ was tested.
asserted
organ → vary → clock
For example, the drugs slowed down aging as much as four years in the case of a clock that looked at heart proteins.
asserted
that → slow → proteins
Overall, though, both studies found that the drugs slowed down molecular time in a significant way.
asserted
drugs → find → way
Multiple other studies have shown that GLP-1s improve health metrics like high blood pressure and cholesterol through a combination of weight loss and weight-independent mechanisms, both of which also affect biological aging.
asserted
both → show → aging
However, it’s unclear whether they would have the same anti-aging effects on a healthy population as they did on patients with obesity or type 2 diabetes.
uncertain
they → ’ → obesity
And while the medications do come with a host of side effects and adverse events, the research is pointing to a significant benefit in aging and longevity.
“All the clocks are telling a consistent story that we’re seeing a reduction in age,” vice president for aging research at Lilly, Kevin Duffin, said during the conference.
asserted
Duffin → come → conference
“It’s not like we’re going to reverse age by 30 years or something, but it’s a significant reduction.
asserted
it → ’ → years
And more companies are investing in the anti-aging effects of the medications, with US agency ARPA-H putting $38 million toward a study that will look at whether semaglutide affects cognition, mobility and sensory acuity in healthy people over 60.
asserted
semaglutide → invest → 60
The Aporia
